{"filings":[{"id":2171486,"accession_number":"0001493152-26-036977","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2026-08-11T11:00:24+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran reports first CIDP patient on PLICID shows functional gains; no adverse events","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First CIDP patient treated with once-weekly IV PLICID regained finger use and ability to walk miles.","No adverse events reported during treatment; company cites case as supporting further evaluation.","PLICID is an ASI-designed galectin antagonist; Bioxytran plans a larger clinical study.","Company acknowledges single-patient observations are not sufficient to establish safety or efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104133,"accession_number":"0001493152-26-011755","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Bioxytran completes $1.2M private placement, issues 21.1M shares and 19.8M warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $1.2 million from sale of 21,071,667 shares at $0.055 per share.","Warrants issued to purchase up to 19,750,001 shares at $0.12 per share, exercisable immediately for five years.","Net proceeds to fund working capital, development programs, and commercialization of A-SUQAR dietary supplement.","Transaction closed March 18, 2026; securities sold to accredited investors under Regulation D exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104132,"accession_number":"0001493152-26-010045","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["3.03","5.02","5.03","9.01"],"status":"ready","headline":"Bioxytran amends preferred stock conversion rights, grants CEO 6M preferred shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment requires both Board and majority of Preferred holders to approve any conversion of Convertible Preferred Stock into common shares.","Filing effective Feb 18, 2026 with Nevada Secretary of State.","CEO David Platt granted 6,000,000 shares of Convertible Preferred Stock as performance-based equity award.","Grant tied to execution of first commercial distribution agreement and capital funding initiatives.","Aligns executive incentives with commercialization and capital formation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104131,"accession_number":"0001493152-26-008475","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran's ProLectin-M achieves 90% Day-5 viral clearance in Phase 1b/2a COVID-19 study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b/2a trial: 39 patients; highest dose 16,800 mg/day showed 90% Day-5 viral clearance vs 20% placebo (p=0.001).","90% of highest-dose cohort had ≥2-point improvement on WHO Ordinal Scale by Day 5 vs 20% placebo.","No serious adverse events, no treatment-related discontinuations; favorable safety profile across all doses.","ProLectin-M targets galectins to block viral entry; potential broad-range antiviral beyond COVID-19.","Company plans larger studies to evaluate ProLectin-M as first-line oral antiviral therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104130,"accession_number":"0001493152-26-006891","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bioxytran signs distribution deal with Khoury Medical for A-SUQAR supplement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Khoury Medical to commercialize A-SUQAR, a chewable blood sugar supplement using Bioxytran's PHGG formulation.","CEO David Platt says deal marks transition from development-stage to recurring commercial revenue while preserving IP ownership.","Volume-based marketplace exclusivity possible if defined purchase thresholds are met, per agreement terms.","Initial commercial shipments expected after completion of standard launch preparations; manufacturing by Bioxytran's OEM.","Bioxytran retains full IP; deal applies only to non-pharmaceutical dietary products, preserving pharma/antiviral programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104129,"accession_number":"0001493152-26-006081","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran reports Phase 2 ProLectin-M shows 100% viral clearance at day 7; p=0.001","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of treated subjects achieved complete viral clearance by Day 7 vs placebo (p=.001).","No viral rebounds observed during the 14-day post-treatment observation period.","16 of 38 subjects had non-detection by Day 5; 1 of 38 by Day 3.","Phase 2 dose-optimization trial: randomized, double-blind, 38 subjects completed.","Company plans regulatory discussions for late-stage development and additional viral indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104128,"accession_number":"0001493152-26-000418","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bioxytran terminates Officer Mike Sheikh; Sheikh contests dismissal reason affecting severance","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Mike Sheikh terminated as an Officer effective December 29, 2025.","Sheikh sent letter on December 31, 2025 contesting reason for dismissal.","Contest outcome will determine if any severance benefits are paid.","No replacement officer named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120397,"accession_number":"0001493152-25-027639","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director resigns citing governance concerns; Bioxytran hires independent expert for controls review","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anders Utter resigns from Bioxytran's Board and Audit Committee chair, effective Dec 7, 2025, citing need for enhanced oversight and controls.","Utter's recommendations included strengthening segregation of duties, improving financial approval documentation, and legal review of a recent stock issuance.","Company engages an independent third-party financial expert to review oversight, internal controls, and approval processes.","No disagreement related to financial statements, accounting practices, or SEC disclosures, per filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154247,"accession_number":"0001641172-25-002602","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K/A","filed_at":"2025-04-03T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bioxytran acquires NDPD Pharma in $15.85M stock deal; CFO adopts 10b5-1 plan","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of NDPD Pharma for 3,389,169 common shares and 28,467,564 preferred shares valued at ~$12.46M.","NDPD held patents for PLM (PHGG) to treat COVID-19 and 60+ viruses; appraised asset value $15.85M including license.","Related-party accounting (ASC 805-50) requires purchase price of $12.47M to be eliminated against equity, not recorded as assets.","CFO Ola Soderquist adopted a 10b5-1 plan to sell up to 500,000 shares by Dec 31, 2025, contingent on price thresholds.","NDPD was beneficially owned by company officers; transaction approved by board as a related-party acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172839,"accession_number":"0001493152-25-003136","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["1.01","8.01","3.02","9.01"],"status":"ready","headline":"Bioxytran secures $1.6M stock purchase with Triton Funds; management forfeits $460K salaries","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Triton Funds LP commits up to $1.6M for up to 17.5M shares (19.9%) at lowest traded price 10 days prior to closing.","Proceeds: $805,000 to extinguish an existing note; balance for pre-clinical/clinical trials and working capital.","Management forfeits more than $460,000 in accrued salaries and expenses to support the transaction.","Closing requires effectiveness of a Form S-1 registration statement to be filed within 7 days; Triton gets $35,000 admin fee.","The deal follows Triton's prior investment; it aims to remove convertible note overhang and fund development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172838,"accession_number":"0001493152-25-001891","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["4.02","9.01"],"status":"ready","headline":"BioXytran restates 2022-2023 financials on share valuation errors; non-reliance on prior filings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss for 2023 increased by $192,523 to $4.56M; for 2022 increased by $9,202 to $2.67M.","Restatement driven by misvaluation of shares under Rule 3(a)(9) and Rule 701, and timing errors in accruals.","Company engaged Fruci & Associates as successor auditor after SEC denied BF Borgers privilege.","Common stock adjusted (1M shares returned to treasury in 2023; 93,750 shares added in 2022).","No net impact on cash flows from operations, investing, or financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172837,"accession_number":"0001493152-25-001603","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran publishes preprint on galectin-3's role in ICI resistance and potential enhancement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preprint reviews theories that galectin-3 contributes to ICI resistance; galectin-3 antagonists may reverse effect.","90% of high galectin-3 NSCLC patients failed to respond to ICI after 3 treatments.","Surface Plasmon Resonance and cryo-EM confirm galectin-3 blocks ICI binding to PD-1 receptor.","Company also published cancer presentation on galectin antagonists in cancer.","CEO states findings herald significant shift in cancer treatment paradigms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189848,"accession_number":"0001493152-24-042741","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bioxytran acquires NDPD Pharma for $15.85M in stock; CFO adopts 10b5-1 plan","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of NDPD Pharma for stock: 3.39M common shares at $0.109 and 28.47M preferred shares at $0.543.","NDPD holds patents for ProLectin-M (COVID-19, RSV, H1N1, etc.) and a license agreement valued at $8.19M.","CFO Ola Soderquist adopted 10b5-1 plan to sell up to 500,000 common shares through March 31, 2025.","Consideration includes 14.1M Bioxytran preferred shares returned to treasury with a $4.0M book value.","Goodwill of $5.38M recorded; intangible assets amortized over 18 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206361,"accession_number":"0001493152-24-033314","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["3.03","8.01","9.01"],"status":"ready","headline":"Bioxytran issues 28.97M preferred shares to insiders, converts 94M common shares and $354K debt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 28,971,248 convertible preferred shares to insiders in exchange for 94,057,658 common shares at a 5:1 ratio.","Preferred shares have super voting rights: vote on 'as if converted' basis multiplied by 2; insiders now control 77.9% voting power.","Conversion also extinguished $353,840 in accrued salaries, accounts receivable, and short-term debt plus 14.41M subsidiary shares.","Common shares outstanding reduced to 81,850,495; par value $0.001 per share; listed on OTCQB.","Press release announces peer-reviewed British Journal article on carbon monoxide in mitochondria, using MDX Viewer to validate BXT-25."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206360,"accession_number":"0001493152-24-028081","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bioxytran launches JV with Heme Foundation for universal oxygen carrier; up to $10M pledged","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["JV with Heme Foundation and NDPD Pharma to develop Universal Oxygen Carrier (UOC) as blood substitute.","Heme Foundation pledges up to $10M over project; $2M already invested in prototypes and compounds.","Total development cost estimated $20M-$25M over 3.5 to 5 years; Bioxytran retains IP.","Two successful small animal trials (mice, rabbits) completed; large 14-day toxicology study planned.","UOC compatible with all blood types, shelf-stable 5+ years, 18-hour half-life, no known side effects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206359,"accession_number":"0001493152-24-026269","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran announces Springer book linking hyperbaric oxygenation to BXT-25 drug","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Book by Prof. Mayevsky published by Springer; covers hyperbaric oxygenation and mitochondrial activity.","BXT-25 is an acellular oxygen carrier (AOC) 5,000x smaller than RBC; aims to replace HBOT.","MDX Viewer (FDA-approved) measures tissue oxygenation via Brain Metabolic Score (BMS).","BMS used as biomarker to demonstrate efficacy in upcoming stroke and Alzheimer's trials.","Company expects coupling BXT-25 with MDX Viewer could shorten clinical trial timelines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223474,"accession_number":"0001493152-24-018484","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Bioxytran dismisses BF Borgers, appoints Fruci & Associates as new auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dismissed BF Borgers CPA PC as independent auditor effective May 7, 2024.","Appointed Fruci & Associates II, PLLC as new independent accountants.","No disagreements or reportable events occurred during 2022-2023 or through March 31, 2024.","Change was recommended by Audit Committee and approved by Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223473,"accession_number":"0001493152-24-015344","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["3.03","5.02","9.01"],"status":"ready","headline":"Bioxytran creates insider-only convertible preferred with 10 votes per share; appoints Dr. Radka Milanova to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board designated 49.5M of 50M authorized preferred shares as Convertible Preferred Stock with 10 votes per share on as-converted basis.","Exchange ratio: 5 common shares for 1 preferred share; conversion ratio: 1 preferred share for 5 common shares.","Only common shares held by insiders (officers, directors) are eligible to exchange into the new preferred stock.","Dr. Radka Milanova (PhD, Organic Chemistry) appointed to fill board vacancy left by deceased Dr. Chen-Walden.","Dr. Milanova receives $5,000 in common stock per attended board/committee meeting; no cash compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277583,"accession_number":"0001493152-23-030051","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2023-08-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran receives FDA clearance to initiate clinical trials for ProLectin-M in COVID-19","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND No. 153742 for ProLectin-M, an oral galectin antagonist for mild-to-moderate COVID-19.","ProLectin-M is Bioxytran's first program to enter the clinic; it aims to showcase broad-spectrum antiviral potential.","Prior phase 2 trial showed 100% PCR-negative by day 7 and 88% by day 3; no viral rebounds.","Company preparing for Phase 3 to seek regulatory approval of ProLectin-M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295558,"accession_number":"0001493152-23-020822","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Bioxytran secures $500k equity investment from Triton Funds for COVID-19 trial funding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Triton Funds LP to purchase 1,612,903 shares at $0.31/share, totaling $500,000.","Proceeds will fund dosage optimization study for mild-moderate COVID-19; dosing expected within month.","Funding sufficient to reach Phase 3 regulatory submission milestone in India.","Triton is second institutional investor alongside Walleye Capital (over $5B AUM).","Company also amended WallachBeth engagement for brokerage of notes totaling $1.165M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316092,"accession_number":"0001493152-23-006937","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Bioxytran dismisses auditor Pinnacle, engages BF Borgers; prior reports had going concern qualification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board dismissed Pinnacle Accountancy Group and engaged BF Borgers CPA PC as independent auditor, effective March 6, 2023.","No disagreements with Pinnacle on accounting principles or disclosures; prior reports contained a going concern qualification.","Material weaknesses in internal control over financial reporting were disclosed in prior 10-K filings for 2021 and 2020.","Pinnacle's letter to SEC confirming agreement with statements in the 8-K is attached as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316091,"accession_number":"0001493152-23-003646","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2023-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran receives CDSCO approval for first-in-human ProLectin-I trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["India's CDSCO granted IND authorization (CT-06, No. CT/ND/03/2023) to evaluate ProLectin-I injection.","Trial will assess safety, tolerability, PK/PD; results to guide Phase II in Long COVID and IPF.","Separate approval from prior ProLectin-M authorization (Dec 2, 2022).","ProLectin-I targets viral persistence and fibrosis; Long COVID affects 65-100 million worldwide.","Trial at each site requires ethics committee approval before initiation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334407,"accession_number":"0001493152-22-035377","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2022-12-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran registers Indian subsidiary, Pharmalectin India, to commercialize ProLectin-M pending CDSCO approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Wholly owned subsidiary Pharmalectin India Private Limited registered on Sept 7, 2022 in India.","Subsidiary to sponsor clinical trials and commercialize Bioxytran's products if CDSCO approval is obtained.","Indian manufacturing plant is FDA-approved; no distributor identified yet.","Press release and updated corporate presentation issued Dec 14, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334406,"accession_number":"0001493152-22-034814","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran receives CDSCO approval for Phase 1b/2a trial of ProLectin-M in COVID-19 patients","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["IND authorization from India's CDSCO for a Phase 1b/2a randomized, blinded, placebo-controlled study of ProLectin-M in mild-to-moderate COVID-19.","Trial will evaluate safety, efficacy, and pharmacokinetics of oral ProLectin-M; results to guide a 408-patient Phase III trial.","Condition: each site must obtain Ethics Committee approval before starting enrollment.","Press release issued December 8, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334405,"accession_number":"0001493152-22-032573","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2022-11-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran Phase 2 trial of ProLectin-M shows 100% viral clearance at day 7 in COVID-19 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of treated patients achieved viral clearance by day 7 vs 6% placebo (p=.001); 88% by day 3 vs 0% placebo.","No drug-related serious adverse events or viral rebounds during 14-day observation period.","NMR data show ProLectin-M binds galectin-3 with micromolar affinity (2 μM) and blocks S1 subunit and ACE2 receptors.","Results provide rationale for upcoming Phase 2/3 registrational trial.","Company plans to explore the galectin antagonist platform for other viruses and indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334404,"accession_number":"0001493152-22-031579","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bioxytran modifies officer severance terms after $1.27M salary forfeiture","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Officers forfeited $1,273,000 in accrued salaries and benefits on Aug 1, 2022.","New severance: 3x annual salary plus target bonus (2x if within 12 months of change of control).","Continued health coverage for 12 months and outplacement up to $50,000 provided.","Amendment replaces prior $100,000 lump-sum severance provision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351830,"accession_number":"0001493152-22-023258","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2022-08-17T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Bioxytran raises $600K in private placement for Covid-19, lung fibrosis clinical trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1.4M shares at $0.4286/share to an accredited investor for gross proceeds of $600,000.","Net proceeds of $576,000 after 4% placement agent fee paid to WallachBeth Capital.","Proceeds intended for down-payment on human trials of ProLectin-M (oral) for Covid-19 and ProLectin-I (IV) for lung fibrosis.","Shares offered on best-efforts basis; no minimum offering amount; funds available immediately upon acceptance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351829,"accession_number":"0001493152-22-020817","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran publishes positive peer-reviewed data for ProLectin-M and PLG-007 drug candidates","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["August 1, 2022 article in Int. J. Health Sciences: ProLectin-M blocks SARS-CoV-2 in vitro; all 5 COVID-19 patients achieved complete remission, zero hospitalization.","July 13, 2022 article in Int. J. Molecular Science: PLG-007 component GMα competitively inhibits α-amylase, maltase, and lactase with Ki of 2.1×10^-6M.","Press release issued August 1, 2022 announcing the ProLectin-M peer-reviewed article and supporting mechanism of action data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369264,"accession_number":"0001539497-22-001158","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bioxytran announces PCT publication of two COVID-19 treatment patents and USPTO trademark approval for ProLectin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PCT published patent WO 2022/099052 for polysaccharides treating SARS-CoV-2, filed Nov 2021.","PCT published patent WO 2022/099061 for IV-administered pectin polysaccharides treating SARS-CoV-2.","USPTO approved trademark 'ProLectin' for publication in Trademark Official Gazette on June 28, 2022.","Both patents claim priority date of November 6, 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388458,"accession_number":"0001539497-22-000063","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2022-01-14T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Bioxytran issues $1.467M in 1-year 6% convertible notes at $0.25; also releases corporate presentation","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered 34 Note Purchase Agreements for $1,467,000 principal in convertible notes due Jan 10, 2023; 6% interest, conversion at $0.25/share.","Net cash reduced by $86,040; aggregate discount of $128,290 includes 264,060 five-year warrants at $0.25 issued to placement agent WallachBeth Capital.","Board approved the agreements on Jan 10, 2022; notes issued same day.","Filed corporate presentation (Exhibit 99.1) on Jan 12, 2022 outlining pharmaceutical development status (no specific content provided)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425399,"accession_number":"0001539497-21-001048","cik":1445815,"company_name":"BIOXYTRAN, INC","ticker":"BIXT","form_type":"8-K","filed_at":"2021-07-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Bioxytran director Henry Esber resigns; Hana Chen-Walden appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Henry Esber resigned as director effective July 15, 2021, for medical reasons.","Hana Chen-Walden, M.D., a Medical Advisory Board member, elected to fill the vacancy.","Dr. Chen-Walden has 35+ years of regulatory experience; she will receive no cash compensation as director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2966950.9999999995,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}